DE102007042154A1 - Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel - Google Patents
Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel Download PDFInfo
- Publication number
- DE102007042154A1 DE102007042154A1 DE102007042154A DE102007042154A DE102007042154A1 DE 102007042154 A1 DE102007042154 A1 DE 102007042154A1 DE 102007042154 A DE102007042154 A DE 102007042154A DE 102007042154 A DE102007042154 A DE 102007042154A DE 102007042154 A1 DE102007042154 A1 DE 102007042154A1
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- amino
- phenylsulfonyl
- alkyl
- phosphonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N C1CCOCC1 Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N C1CCSCC1 Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N C1CNCCNC1 Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N C1COCCNC1 Chemical compound C1COCCNC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N C1NCCNC1 Chemical compound C1NCCNC1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N C1NCCOC1 Chemical compound C1NCCOC1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N C1NCCSC1 Chemical compound C1NCCSC1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- XABYCTJRTCHRAO-UHFFFAOYSA-N CC(C)OC(OCOP(CN(c(cc1)cc2c1c(C(NC)=O)ccc2)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCOC(OC(C)C)=O)=O)=O Chemical compound CC(C)OC(OCOP(CN(c(cc1)cc2c1c(C(NC)=O)ccc2)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCOC(OC(C)C)=O)=O)=O XABYCTJRTCHRAO-UHFFFAOYSA-N 0.000 description 1
- DWMKTVVKCPBRRF-UHFFFAOYSA-O CCOP(C(N(c1c(cccc2C(NCCc3ccccc3)=O)c2ccc1)S(c1cc(Cl)cc(Cl)c1)(=O)=O)[OH+]CC)=O Chemical compound CCOP(C(N(c1c(cccc2C(NCCc3ccccc3)=O)c2ccc1)S(c1cc(Cl)cc(Cl)c1)(=O)=O)[OH+]CC)=O DWMKTVVKCPBRRF-UHFFFAOYSA-O 0.000 description 1
- RUKPXORVRNKAPH-UHFFFAOYSA-N CCOP(CN(c(cc1)cc(cc2)c1cc2NC(OC(C)(C)C)=O)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCC)=O Chemical compound CCOP(CN(c(cc1)cc(cc2)c1cc2NC(OC(C)(C)C)=O)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCC)=O RUKPXORVRNKAPH-UHFFFAOYSA-N 0.000 description 1
- RNUYAKZRJRJYRD-UHFFFAOYSA-N CCOP(CN(c(cc1)cc2c1c(C(NCc(cc1)ccc1C#N)=O)ccc2)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCC)=O Chemical compound CCOP(CN(c(cc1)cc2c1c(C(NCc(cc1)ccc1C#N)=O)ccc2)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCC)=O RNUYAKZRJRJYRD-UHFFFAOYSA-N 0.000 description 1
- NLDGVVIAAYHZKC-UHFFFAOYSA-N CCOP(CN(c(ccc1c2)cc1ccc2-c1ncccn1)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCC)=O Chemical compound CCOP(CN(c(ccc1c2)cc1ccc2-c1ncccn1)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCC)=O NLDGVVIAAYHZKC-UHFFFAOYSA-N 0.000 description 1
- KRPSUAJHMSCEQE-UHFFFAOYSA-N CCOP(CN(c1c(cccc2)c2ccc1)S(c1cc(C(F)(F)F)cc(Cl)c1)(=O)=O)(OCC)=O Chemical compound CCOP(CN(c1c(cccc2)c2ccc1)S(c1cc(C(F)(F)F)cc(Cl)c1)(=O)=O)(OCC)=O KRPSUAJHMSCEQE-UHFFFAOYSA-N 0.000 description 1
- XJDOOLQDMRVKLV-UHFFFAOYSA-N CCOP(CN(c1cc2cccc(C(NC)=O)c2cc1)S(c1cc(C)cc(C)c1)(=O)=O)(OCC)=O Chemical compound CCOP(CN(c1cc2cccc(C(NC)=O)c2cc1)S(c1cc(C)cc(C)c1)(=O)=O)(OCC)=O XJDOOLQDMRVKLV-UHFFFAOYSA-N 0.000 description 1
- CLBSNSZHIMURRN-UHFFFAOYSA-N CCOP(CN(c1cccc2c1cccc2)S(c1cc(Br)cc(C)c1)(=O)=O)(OCC)=O Chemical compound CCOP(CN(c1cccc2c1cccc2)S(c1cc(Br)cc(C)c1)(=O)=O)(OCC)=O CLBSNSZHIMURRN-UHFFFAOYSA-N 0.000 description 1
- GKFJNLQHWJROSO-UHFFFAOYSA-N CCOP(CN(c1cccc2c1ncnc2N(C)C)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCC)=O Chemical compound CCOP(CN(c1cccc2c1ncnc2N(C)C)S(c1cc(Cl)cc(Cl)c1)(=O)=O)(OCC)=O GKFJNLQHWJROSO-UHFFFAOYSA-N 0.000 description 1
- IPGVCTUENXZDCK-UHFFFAOYSA-N CCOP(CNc(c1ccccc1cc1)c1C(N)=O)(OCC)=[O]c(c(Cl)cc(Cl)c1)c1S(=O)=O Chemical compound CCOP(CNc(c1ccccc1cc1)c1C(N)=O)(OCC)=[O]c(c(Cl)cc(Cl)c1)c1S(=O)=O IPGVCTUENXZDCK-UHFFFAOYSA-N 0.000 description 1
- GAEFMEGSGIGBEG-UHFFFAOYSA-N CN(Cc1ccccc1)C(c1cccc2c1cccc2N(CP(O)(O)=O)S(c1cc(Cl)cc(Cl)c1)(O)=O)=O Chemical compound CN(Cc1ccccc1)C(c1cccc2c1cccc2N(CP(O)(O)=O)S(c1cc(Cl)cc(Cl)c1)(O)=O)=O GAEFMEGSGIGBEG-UHFFFAOYSA-N 0.000 description 1
- OELBTWJIOKIWPN-UHFFFAOYSA-N C[O](c1cccc(cc2)c1c(N)c2C#[Si](C)(C)C)[SH+](c1cc(Cl)cc(Cl)c1)=O Chemical compound C[O](c1cccc(cc2)c1c(N)c2C#[Si](C)(C)C)[SH+](c1cc(Cl)cc(Cl)c1)=O OELBTWJIOKIWPN-UHFFFAOYSA-N 0.000 description 1
- JEJAMFJGBMCRGT-UHFFFAOYSA-N Cc(ccc1c2nccc1)c2N(CP(O)(O)=O)S(c1cc(Cl)cc(Cl)c1)(=O)=O Chemical compound Cc(ccc1c2nccc1)c2N(CP(O)(O)=O)S(c1cc(Cl)cc(Cl)c1)(=O)=O JEJAMFJGBMCRGT-UHFFFAOYSA-N 0.000 description 1
- BSYSYHSTNHHVJL-UHFFFAOYSA-N Cc1cc(Br)cc(S(Cl)(=O)=O)c1 Chemical compound Cc1cc(Br)cc(S(Cl)(=O)=O)c1 BSYSYHSTNHHVJL-UHFFFAOYSA-N 0.000 description 1
- RJFHWGYLSUAYKE-UHFFFAOYSA-N Cc1cc(C)cc(S(Nc2cc3cccc(C(NC)=O)c3cc2)(=O)=O)c1 Chemical compound Cc1cc(C)cc(S(Nc2cc3cccc(C(NC)=O)c3cc2)(=O)=O)c1 RJFHWGYLSUAYKE-UHFFFAOYSA-N 0.000 description 1
- ZRLIFEQCMCLKDP-UHFFFAOYSA-O Cc1cc(C)cc([SH+](N(CP(O)(O)=O)c2cccc3c2cccc3C(NC)=O)=O)c1 Chemical compound Cc1cc(C)cc([SH+](N(CP(O)(O)=O)c2cccc3c2cccc3C(NC)=O)=O)c1 ZRLIFEQCMCLKDP-UHFFFAOYSA-O 0.000 description 1
- GYBYSLZSCPDOTM-UHFFFAOYSA-N Cc1cc(c(NS(c2cc(Cl)cc(Cl)c2)(=O)=O)ccc2)c2cn1 Chemical compound Cc1cc(c(NS(c2cc(Cl)cc(Cl)c2)(=O)=O)ccc2)c2cn1 GYBYSLZSCPDOTM-UHFFFAOYSA-N 0.000 description 1
- HLYXLDPXCYQLSP-UHFFFAOYSA-N Cc1cc2ccccc2cc1N(CP(O)(O)=O)S(c1cc(Cl)cc(Cl)c1)(=O)=O Chemical compound Cc1cc2ccccc2cc1N(CP(O)(O)=O)S(c1cc(Cl)cc(Cl)c1)(=O)=O HLYXLDPXCYQLSP-UHFFFAOYSA-N 0.000 description 1
- IJBAFQCBVPHDKE-UHFFFAOYSA-N N#Cc1ccc(CNC(c2c(ccc(N(CP(O)(O)=O)S(c3cc(Cl)cc(Cl)c3)(=O)=O)c3)c3ccc2)=O)cc1 Chemical compound N#Cc1ccc(CNC(c2c(ccc(N(CP(O)(O)=O)S(c3cc(Cl)cc(Cl)c3)(=O)=O)c3)c3ccc2)=O)cc1 IJBAFQCBVPHDKE-UHFFFAOYSA-N 0.000 description 1
- FKPOFPSUEPTJCZ-UHFFFAOYSA-N Nc(c1ccccc1cc1)c1C(N1CCCC1)=O Chemical compound Nc(c1ccccc1cc1)c1C(N1CCCC1)=O FKPOFPSUEPTJCZ-UHFFFAOYSA-N 0.000 description 1
- WLEFUJADNZSOIW-UHFFFAOYSA-N Nc1cc(Cl)cc(S(N(CP(O)(O)=O)c2cccc3c2cccc3)(=O)=O)c1 Chemical compound Nc1cc(Cl)cc(S(N(CP(O)(O)=O)c2cccc3c2cccc3)(=O)=O)c1 WLEFUJADNZSOIW-UHFFFAOYSA-N 0.000 description 1
- BXIQUCBGNORMIL-UHFFFAOYSA-N O=C(c(ccc1c2cccc1)c2NS(c1cc(Cl)cc(Cl)c1)(=O)=O)N1CCCC1 Chemical compound O=C(c(ccc1c2cccc1)c2NS(c1cc(Cl)cc(Cl)c1)(=O)=O)N1CCCC1 BXIQUCBGNORMIL-UHFFFAOYSA-N 0.000 description 1
- OPBLMUCYLATNGT-UHFFFAOYSA-N O=C(c1ccccc1)c(ccc1c2cccc1)c2NS(c1cc(Cl)cc(Cl)c1)(=O)=O Chemical compound O=C(c1ccccc1)c(ccc1c2cccc1)c2NS(c1cc(Cl)cc(Cl)c1)(=O)=O OPBLMUCYLATNGT-UHFFFAOYSA-N 0.000 description 1
- TVNXVTHWGFPUFR-UHFFFAOYSA-N O=S(c1cc(Br)cc(Cl)c1)(Cl)=O Chemical compound O=S(c1cc(Br)cc(Cl)c1)(Cl)=O TVNXVTHWGFPUFR-UHFFFAOYSA-N 0.000 description 1
- LAOHVJMVSKGUDI-UHFFFAOYSA-N O=S(c1cc(Cl)cc(Cl)c1)(Nc(c(cccc1)c1cc1)c1Cl)=O Chemical compound O=S(c1cc(Cl)cc(Cl)c1)(Nc(c(cccc1)c1cc1)c1Cl)=O LAOHVJMVSKGUDI-UHFFFAOYSA-N 0.000 description 1
- TVETWDSJSSJMNP-UHFFFAOYSA-O O[S+](c1cc(Cl)cc(Br)c1)(Nc1cccc2c1cccc2)=O Chemical compound O[S+](c1cc(Cl)cc(Br)c1)(Nc1cccc2c1cccc2)=O TVETWDSJSSJMNP-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007042154A DE102007042154A1 (de) | 2007-09-05 | 2007-09-05 | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| PCT/EP2008/061651 WO2009030715A1 (en) | 2007-09-05 | 2008-09-04 | Arylsulfonylaminomethylphosphonic acid derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| US12/676,319 US8163911B2 (en) | 2007-09-05 | 2008-09-04 | Arylsulfonylaminomethylphosphonic acid derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| JP2010523500A JP2010538040A (ja) | 2007-09-05 | 2008-09-04 | アリールスルホニルアミノメチルホスホン酸誘導体、その製法及びその医薬組成物としての使用 |
| CA2698486A CA2698486A1 (en) | 2007-09-05 | 2008-09-04 | Arylsulfonylaminomethylphosphonic acid derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| EP08803622A EP2200987A1 (en) | 2007-09-05 | 2008-09-04 | Arylsulfonylaminomethylphosphonic acid derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007042154A DE102007042154A1 (de) | 2007-09-05 | 2007-09-05 | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102007042154A1 true DE102007042154A1 (de) | 2009-03-12 |
Family
ID=39967609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102007042154A Withdrawn DE102007042154A1 (de) | 2007-09-05 | 2007-09-05 | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8163911B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2200987A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010538040A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2698486A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE102007042154A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009030715A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007012284A1 (de) | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035334A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007042154A1 (de) | 2007-09-05 | 2009-03-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102008019838A1 (de) * | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9326295B1 (en) | 2014-12-10 | 2016-04-26 | Sony Corporation | Method and apparatus for transmitting a-priori information in a communication system |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2759228B2 (ja) | 1992-05-21 | 1998-05-28 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
| TW260664B (cg-RX-API-DMAC7.html) | 1993-02-15 | 1995-10-21 | Otsuka Pharma Factory Inc | |
| DE19753522A1 (de) | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma | Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel |
| JP2000247949A (ja) | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
| GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| US6498151B2 (en) | 2000-03-22 | 2002-12-24 | Merck Frosst Canada & Co. | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| GB0110797D0 (en) * | 2001-05-02 | 2001-06-27 | Celltech R&D Ltd | Chemical compounds |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| DE10215907A1 (de) | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
| US7223796B2 (en) | 2002-04-11 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use |
| DE50311923D1 (de) | 2002-07-11 | 2009-10-29 | Sanofi Aventis Deutschland | Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| US7262220B2 (en) | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
| AU2003249937A1 (en) | 2002-07-12 | 2004-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| EP1636224B1 (en) | 2003-05-21 | 2010-07-14 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase |
| ES2222827B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222832B1 (es) | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222829B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| EP1513085A1 (en) | 2003-09-08 | 2005-03-09 | Abb Research Ltd. | Method of scheduling maintenance actions |
| JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
| KR20070115865A (ko) | 2004-09-21 | 2007-12-06 | 아더시스 인코포레이티드 | Ｃｒｔｈ2 수용체 길항작용을 나타내는 벤즈이미다졸아세트산 및 이의 용도 |
| NZ554783A (en) * | 2004-11-15 | 2010-12-24 | Ceptyr Inc | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| HRP20140975T1 (hr) * | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| DE102007007751A1 (de) | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2008103354A2 (en) | 2007-02-20 | 2008-08-28 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| DE102007012284A1 (de) | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035334A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007042154A1 (de) | 2007-09-05 | 2009-03-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
-
2007
- 2007-09-05 DE DE102007042154A patent/DE102007042154A1/de not_active Withdrawn
-
2008
- 2008-09-04 WO PCT/EP2008/061651 patent/WO2009030715A1/en not_active Ceased
- 2008-09-04 CA CA2698486A patent/CA2698486A1/en not_active Abandoned
- 2008-09-04 JP JP2010523500A patent/JP2010538040A/ja active Pending
- 2008-09-04 EP EP08803622A patent/EP2200987A1/en not_active Withdrawn
- 2008-09-04 US US12/676,319 patent/US8163911B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
Non-Patent Citations (29)
| Title |
|---|
| A.G. Mitchell et al. Journal of the Chemical Society, Perkin Transactions I 1992, 2345 |
| Allinger N. L. und Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley lnterscience, 1971 |
| Boronic Acids; Preparation and Applications in Organic Synthesis and Medicine, D. G. Hall Hrsg., WILEY-VCH 2005, S. 28 ff |
| C. Ballstore et al. Bioorganic & Medicinal Chemistry Letters 2001, 1, 1053 |
| C. Meier et al. Journal of Medicinal Chemistry 2005, 48, 8079 |
| Cohen et al., Methods Enzymol. 1988, Vol 159 pp 390 |
| D. M. T. Chan et al., Tetrahedron Lett. 1998, 39, 2933 |
| F. Puech et al. Antiviral Research 1993, 22, 155 |
| G. J. Friis und H. Bundgaard, European Journal of Pharmaceutical Sciences 1996, 4, 49 |
| H. T. Serafinowska et al. Journal of Medicinal Chemistry 1995, 38, 1372 |
| J. E. Starret et al. Journal of Medicinal Chemistry 1994, 37, 1857 |
| J. P. Krise und V. J. Stella in Advanced Drug Delivery Reviews 1996, 19, 287 |
| M. D. Erion et al. Journal of Pharmacology and Experimental Therapeutics 2005, 312, 554 |
| M. D. Erion et al. Journal of the American Chemical Society 2004, 126, 5145 |
| M. Murata et al., J. Org. Chem. 1997; 62, 6458 |
| M. Murata et al., J. Org. Chem. 2000; 65, 164 |
| N. Miyaura et al., Tetrahedron Lett. 1997, 38, 3447 |
| P. Annaert et al. Journal of Pharmaceutical Sciences 2000, 89, 1054 |
| P. Cohen, Nature Reviews Molecular Cell Biology 2006, 7, 867-874 |
| P. Ettmayer et al. Journal of Medicinal Chemistry 2004, 47, 2393 |
| P. Kocienski, Protecting Groups, 3rd ed. 2004, THIEME, Stuttgart, ISBN: 3131370033 |
| Pharmaceutical Salts, S. M. Birge et al., J. Pharm. Sci. 1977, 66, 1-19 |
| R. Ortmann et al. Archiv der Pharmazie - Chemistry in Life Sciences 2005, 338, 305 |
| S. Benzaria et al. Journal of Medicinal Chemistry 1996, 39, 4958 |
| S. De Lombaert et al. Bioorganic & Medicinal Chemistry 1995, 5, 151 |
| S. De Lombaert et al. Journal of Medicinal Chemistry 1994, 37, 498 |
| S. Freeman und K. C. Ross in Progress in Medicinal Chemistry 1997, 34, 111 |
| T. Ishiyama et al., J.Org. Chem. 1995, 60, 7508 |
| V. Gagnard et al. European Journal of Medicinal Chemistry 2003, 38, 883 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2200987A1 (en) | 2010-06-30 |
| CA2698486A1 (en) | 2009-03-12 |
| US8163911B2 (en) | 2012-04-24 |
| US20100261677A1 (en) | 2010-10-14 |
| JP2010538040A (ja) | 2010-12-09 |
| WO2009030715A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7099824B2 (ja) | 抗菌化合物 | |
| EP1641799B1 (de) | Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel | |
| DE102008019838A1 (de) | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel | |
| US8163911B2 (en) | Arylsulfonylaminomethylphosphonic acid derivatives, the preparation thereof and the use thereof as pharmaceutical compositions | |
| DE102007035333A1 (de) | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel | |
| DE102007035334A1 (de) | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel | |
| KR20190018681A (ko) | 항균제로서의 헤테로고리 화합물 | |
| KR20190017948A (ko) | 항균제로서의 헤테로고리 화합물 | |
| EP2635563B1 (en) | Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors | |
| WO2004050658A1 (de) | Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel | |
| DE102004012068A1 (de) | Neue alkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel | |
| EP3906033A1 (en) | Methods and materials for increasing transcription factor eb polypeptide levels | |
| DE10256264A1 (de) | Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel | |
| EP1727798B1 (de) | Neue aryl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel | |
| US10464904B2 (en) | Dextrorphan-derivatives with suppressed central nervous activity | |
| DE10042064A1 (de) | Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
| EP1727812B1 (de) | Neue cycloalkyl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel | |
| CN101541752A (zh) | 抗菌的喹啉衍生物 | |
| EP3296298A1 (de) | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung | |
| DE10309927A1 (de) | Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel | |
| HK40004907A (zh) | 作为抗细菌剂的杂环化合物 | |
| HK40004927A (zh) | 杂环化合物作为抗细菌剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Effective date: 20120403 |